Medranda GA, Brahmbhatt K, Marzo K, et al. - This retrospective, observational study was designed to determine the short-term as well as long-term results of high-risk patients who received transcatheter mitral valve implantation (TMVI) for degenerated mitral bioprostheses. Experts analyzed data on the first 26 patients with previous surgical mitral valve replacement or repair with annular ring that had TMVI using the balloon-expandable heart-valve system from 2014 to 2019. In addition, they analyzed pre/postprocedure echocardiographic data, in-hospital, 30-day data and 1-year results. A 100% device implantation success rate was reported. The in-hospital survival rate was 96%. At 30 days and at 1 year, the survival was estimated to be 96% and 85%, respectively. Findings revealed that significant short-term and sustained long-term improvements in mean mitral gradient, mitral regurgitation and heart failure symptoms were achieved by treating degenerated mitral bioprostheses using TMVI in high-risk patients.